Article
Accuracy of a commercially available assay for HCV genotyping and subtyping in the clinical practice.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology - 1 Sept 2013
González Victoria, Gomes-Fernandes Meissiner, Bascuñana Elisabet, Casanovas Sònia, Saludes Verónica, Jordana-Lluch Elena, Matas Lurdes, Ausina Vicenç, Martró Elisa
Abstract excerpt
BACKGROUND: Hepatitis C virus (HCV) genotyping is mandatory for tailoring dose and duration of pegylated interferon-α plus ribavirin treatment and for deciding on triple therapy eligibility. Additionally, subtyping may play a role in helping to select future treatment regimens that include directly-acting antivirals. However, commercial assays for HCV genotyping fail to identify the genotype/subtype in some...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
